Orphan Drug Designation Provided to a Treatment for Chronic Inflammatory Demyelinating Polyneuropathy
The FDA has just provided Orphan Drug Designation to Hizentra for the treatment of adults diagnosed with chronic inflammatory demyelinating polyneuropathy (CIPD). This is a maintenance therapy which works to…